Clinical trials: Relapsed Adult Acute Myeloid Leukemia
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00047021
- Testing
- sargramostim, cytarabine, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Trial name
- VenBom (NCT05597306)
- Testing
- Bomedemstat, Venetoclax
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Terrence J Bradley, MD
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
- Trial name
- NCT03519984
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design.
- Trial name
- ODYSSEY (NCT05601726)
- Testing
- ABD-3001
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- Advanced BioDesign
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
This phase II trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen matched ex vivo expanded cord blood progenitors with one or two unmanipulated umbilical cord blood units for…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01175785
- Testing
- umbilical cord blood transplantation, fludarabine phosphate, cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nohla Therapeutics, Inc.
Acute Myeloid Leukemia
Venetoclax Registry
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax
- Trial name
- VENreg (NCT03662724)
- Testing
- Venetoclax
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannover Medical School
Acute Myeloid Leukemia
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,
- Trial name
- RADIUS (NCT01883362)
- Testing
- Midostaurin, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00577694
- Testing
- clofarabine, gemtuzumab ozogamicin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
This is a single center, "modified standard design" dose escalation study designed to determine the maximum tolerated, minimum efficacious dose (MTD/MED) of IL-15 (Intravenous Recombinant Human IL-15) and incidence of donor…
- Trial name
- NCT01385423
- Testing
- Preparative Regimen, Intravenous Recombinant Human IL-15 (rhIL-15)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Depression, Fatigue
Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia
RATIONALE: An individualized exercise program may be effective in lessening fatigue and depression and improving quality of life in patients undergoing chemotherapy for leukemia.
- Conditions
- Depression, Fatigue, Leukemia, Musculoskeletal Complications
- Trial name
- NCT00499759
- Testing
- Resting vitals, Body Composition, Timed Get-up and Go test (TGUG).
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
- Trial name
- NCT02333162
- Testing
- Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago